NCT07594431RecruitingPhase 2
Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
A Randomized Phase II Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 12 May 2026
- Start date
- 28 Aug 2026
- Primary completion date
- Aug 2028
- Lead sponsor
- Stanford University
- Diseases
- Childhood cancers
- NCT number
- NCT07594431
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From 28 Aug 2026 to the primary completion date, Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiation therapy to the tumor to be treated
Other illness
- Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome
- The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma
Other
- Active pregnancy
Who the study is looking for
- Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer
- One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: \>2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is \>2.5 cm in short axis
- Age ≥12
- ECOG Performance Status 0-2
- For patients age 12-16, Lansky Play-Performance score 50-100
- Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential
- All patients and/or their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent.
Criteria the registry did not label
- 80 patients with confirmed metastatic tumor (\>2.5 cm in short axis) will be enrolled, all ≥ 12 years of age with ECOG ≤ 2. All genders and races will be included.
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University Coordinator of this site? Confirm its status | Palo Alto | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.